<!DOCTYPE html>
<html lang="en">
<head>
<meta charset="UTF-8">
<meta name="viewport" content="width=device-width, initial-scale=1.0">
<title>Narrative Pivot Memo — Umay Care Holdings</title>
<link href="https://fonts.googleapis.com/css2?family=DM+Serif+Display:ital@0;1&family=DM+Sans:wght@300;400;500;600;700&display=swap" rel="stylesheet">
<style>
  @page { size: A4; margin: 0; }
  * { margin: 0; padding: 0; box-sizing: border-box; }
  body {
    font-family: 'DM Sans', sans-serif; color: #1a1a2e;
    background: #fff; line-height: 1.6; font-size: 13px;
    max-width: 900px; margin: 0 auto;
  }
  .page { padding: 48px 56px; }

  /* Header — heavier, more editorial */
  .header {
    margin-bottom: 32px; padding-bottom: 20px; border-bottom: 4px solid #1a1a2e;
  }
  .header .overline {
    font-size: 11px; font-weight: 700; text-transform: uppercase;
    letter-spacing: 0.12em; color: #5a5a7a; margin-bottom: 8px;
  }
  .header h1 {
    font-family: 'DM Serif Display', serif; font-size: 34px; line-height: 1.15;
    color: #1a1a2e; margin-bottom: 8px;
  }
  .header h1 em { font-style: italic; }
  .header .deck {
    font-size: 15px; color: #5a5a7a; line-height: 1.5; max-width: 700px;
  }

  .meta {
    display: flex; justify-content: space-between; margin-bottom: 28px;
    font-size: 11px; color: #8a8aaa;
  }

  /* Section headers */
  h2 {
    font-family: 'DM Serif Display', serif; font-size: 19px; color: #1a1a2e;
    margin: 28px 0 10px;
  }

  /* Body paragraphs */
  p { margin-bottom: 12px; }
  p.lead { font-size: 14px; line-height: 1.6; }

  /* Evidence callout */
  .evidence {
    background: #f8f8fc; border: 1px solid #e8e8f0; border-radius: 8px;
    padding: 18px 22px; margin: 18px 0;
  }
  .evidence .label {
    font-size: 10px; font-weight: 700; text-transform: uppercase;
    letter-spacing: 0.06em; color: #5a5a7a; margin-bottom: 8px;
  }
  .evidence-grid {
    display: grid; grid-template-columns: repeat(3, 1fr); gap: 16px;
  }
  .ev-item .num {
    font-family: 'DM Serif Display', serif; font-size: 26px; color: #1a1a2e; line-height: 1.1;
  }
  .ev-item .desc { font-size: 11px; color: #5a5a7a; margin-top: 2px; }
  .ev-item .source { font-size: 9px; color: #aaa; margin-top: 2px; }

  /* Insight block */
  .insight {
    background: #1a1a2e; color: #e0e0f0; border-radius: 8px;
    padding: 20px 24px; margin: 22px 0;
  }
  .insight .label {
    font-size: 10px; text-transform: uppercase; letter-spacing: 0.08em;
    color: #9090bb; margin-bottom: 8px;
  }
  .insight p { color: #d0d0e8; margin-bottom: 8px; }
  .insight strong { color: #fff; }

  /* Three lenses */
  .lenses {
    display: grid; grid-template-columns: 1fr 1fr 1fr; gap: 14px; margin: 18px 0;
  }
  .lens {
    border: 1px solid #e0e0e8; border-radius: 8px; padding: 16px;
  }
  .lens .lens-label {
    font-size: 10px; font-weight: 700; text-transform: uppercase;
    letter-spacing: 0.05em; margin-bottom: 6px; padding-bottom: 4px;
    border-bottom: 2px solid;
  }
  .lens.a .lens-label { color: #1e40af; border-color: #1e40af; }
  .lens.b .lens-label { color: #059669; border-color: #059669; }
  .lens.c .lens-label { color: #7c3aed; border-color: #7c3aed; }
  .lens .lens-title { font-weight: 700; font-size: 13px; margin-bottom: 4px; }
  .lens p { font-size: 11px; color: #5a5a7a; margin-bottom: 0; }

  /* Comps strip */
  .comps {
    display: grid; grid-template-columns: repeat(4, 1fr); gap: 1px;
    background: #e0e0e8; border-radius: 8px; overflow: hidden; margin: 18px 0;
  }
  .comp {
    background: #fff; padding: 12px; text-align: center;
  }
  .comp .name { font-weight: 700; font-size: 12px; }
  .comp .approach { font-size: 10px; color: #5a5a7a; margin-top: 2px; }
  .comp .gap { font-size: 10px; color: #dc2626; margin-top: 4px; font-weight: 600; }

  /* Footer */
  .footer {
    margin-top: 28px; padding-top: 14px; border-top: 1px solid #e0e0e8;
    display: flex; justify-content: space-between; font-size: 10px; color: #8a8aaa;
  }

  /* Traction strip */
  .traction {
    display: grid; grid-template-columns: repeat(5, 1fr); gap: 10px; margin: 18px 0;
  }
  .traction-item { text-align: center; }
  .traction-item .num {
    font-family: 'DM Serif Display', serif; font-size: 20px; color: #1a1a2e;
  }
  .traction-item .lbl { font-size: 9.5px; color: #5a5a7a; margin-top: 1px; }
</style>
</head>
<body>

<div class="page">

  <!-- HEADER -->
  <div class="header">
    <div class="overline">Umay Care Holdings Inc. · Investment Memo</div>
    <h1>The eyes tell you what the brain <em>won't.</em></h1>
    <div class="deck">
      Umay is building the first closed-loop system that reads ocular fatigue, delivers precision thermal therapy, and learns from every session — positioning at the intersection of a $6B dry eye market and a $411B sleep economy that nobody else can serve from a single device.
    </div>
  </div>

  <div class="meta">
    <span>Stage 1A · Confidential</span>
    <span>Seeking $2M CAD · Pre-Series A</span>
  </div>

  <!-- THE PROBLEM -->
  <h2>The Problem Nobody's Connecting</h2>
  <p class="lead">344 million people worldwide have dry eye disease. 62% of them also sleep poorly. These aren't unrelated complaints — they're two symptoms of the same vicious cycle, and peer-reviewed research now proves it.</p>

  <div class="evidence">
    <div class="label">Published Evidence Base (Peer-Reviewed)</div>
    <div class="evidence-grid">
      <div class="ev-item">
        <div class="num">3.76×</div>
        <div class="desc">Risk of insufficient sleep in dry eye patients</div>
        <div class="source">Meta-analysis · 21 studies · 419,218 participants</div>
      </div>
      <div class="ev-item">
        <div class="num">$585B</div>
        <div class="desc">Annual presenteeism cost (US employers)</div>
        <div class="source">Integrated Benefits Institute, 2023</div>
      </div>
      <div class="ev-item">
        <div class="num">90%+</div>
        <div class="desc">DED patients non-compliant with Rx within 90 days</div>
        <div class="source">PDC ≥80% adherence: 5.9-9.7%</div>
      </div>
    </div>
  </div>

  <p>Eye doctors treat the eyes. Sleep doctors treat sleep. Nobody treats the connection between them — the shared inflammatory pathways, the circadian disruption, the progressive deterioration where each condition makes the other worse. And the standard treatments fail: over 90% of dry eye patients stop using their prescription drops within three months.</p>

  <!-- THE INSIGHT -->
  <div class="insight">
    <div class="label">The Insight</div>
    <p><strong>People adapt subjectively while deteriorating objectively.</strong> After 14 days of restricted sleep, cognitive impairment rises to the equivalent of legal intoxication — but self-assessed sleepiness plateaus by day 3. The brain stops reporting the problem. The eyes don't.</p>
    <p>Blink rate, tear film stability, pupil dynamics, periocular temperature — these are the honest signals the brain can no longer access. <strong>Umay reads these signals, intervenes with precision thermal therapy, and closes the loop between measurement and treatment.</strong></p>
  </div>

  <!-- THREE LENSES -->
  <h2>Three Ways to Evaluate the Same Company</h2>
  <div class="lenses">
    <div class="lens a">
      <div class="lens-label">Lens A · The Business Today</div>
      <div class="lens-title">Rest: Clinically Validated Hardware</div>
      <p>A patented periocular thermal wearable sold through 134 eye care clinics. 3,000 units shipped. 87% eye comfort improvement. 67% sleep quality improvement. 84% daily usage. 0.67% return rate. Reorder-driven: 93.9% of 2025 volume from existing clinics.</p>
    </div>
    <div class="lens b">
      <div class="lens-label">Lens B · The Measurement Layer</div>
      <div class="lens-title">RestScan: Webcam-Based Biometric Assessment</div>
      <p>A browser-first computer vision tool that reads ocular fatigue via standard webcam. 120-second protocol, 100% local processing. Three signal domains (ocular, autonomic, behavioral). Zero infrastructure cost. Transforms clinic pre-testing and drives patient acquisition.</p>
    </div>
    <div class="lens c">
      <div class="lens-label">Lens C · The System</div>
      <div class="lens-title">The Closed Loop Nobody Else Can Build</div>
      <p>RestScan detects → Rest treats → RestScan measures improvement → algorithm optimizes next session. Each cycle generates paired data (biometric input → therapeutic output) that makes the system smarter. 2,847 active devices × daily use = ~1M sessions/year of proprietary training data.</p>
    </div>
  </div>

  <!-- TRACTION -->
  <h2>Proof Points</h2>
  <div class="traction">
    <div class="traction-item"><div class="num">2,996</div><div class="lbl">Units shipped</div></div>
    <div class="traction-item"><div class="num">134</div><div class="lbl">Clinic partners</div></div>
    <div class="traction-item"><div class="num">N=500</div><div class="lbl">Gov't-backed pilot</div></div>
    <div class="traction-item"><div class="num">3</div><div class="lbl">Issued US patents</div></div>
    <div class="traction-item"><div class="num">1,600+</div><div class="lbl">Unit backlog</div></div>
  </div>

  <!-- GROUND ZERO: WHY NOT THEM -->
  <h2>Why Nobody Else Can Do This</h2>

  <div class="comps">
    <div class="comp">
      <div class="name">IPL / LipiFlow</div>
      <div class="approach">$750-1,500/session, in-office only</div>
      <div class="gap">Can't follow the patient home</div>
    </div>
    <div class="comp">
      <div class="name">Bruder / OTC Masks</div>
      <div class="approach">$20-75, no regulation, no data</div>
      <div class="gap">No measurement, no clinical trust</div>
    </div>
    <div class="comp">
      <div class="name">Oura / Whoop</div>
      <div class="approach">Wrist/ring biometrics</div>
      <div class="gap">No ocular signals, no therapy</div>
    </div>
    <div class="comp">
      <div class="name">Nuralogix / FaceHeart</div>
      <div class="approach">Facial CV measurement</div>
      <div class="gap">No treatment device, no clinical channel</div>
    </div>
  </div>

  <p>Every incumbent faces a structural barrier: in-office DED companies would cannibalize per-session revenue. Consumer device companies lack clinical evidence and clinic trust. Wearable health platforms don't measure the eyes. CV companies don't deliver treatment. <strong>Umay starts at the intersection with a 4-year head start in thermal therapy, 134 clinic relationships, and issued patents covering both the hardware and the sensing-to-relief integration.</strong></p>

  <!-- THE ASK -->
  <div class="insight">
    <div class="label">The Raise</div>
    <p><strong>$2M CAD Pre-Series A.</strong> Use of funds: fulfill 1,600-unit backlog ($500K), activate US clinic channel via 3PL + Head of Growth ($600K), complete Gen 2 DFM + initial production ($500K), RestScan validation + IP prosecution ($200K), working capital ($200K).</p>
    <p>Target: 500+ active clinic partners, US logistics operational, Gen 2 in production, RestScan validated, and positioned for $5-8M Series A within 12-18 months.</p>
  </div>

  <div class="footer">
    <div>Umay Care Holdings Inc. · Edmonton, AB · umay.rest · Ali Habib, CEO</div>
    <div>Confidential — Stage 1A Teaser</div>
  </div>

</div>
</body>
</html>
